Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Interleukin-17 is a favorable prognostic marker for colorectal cancer.

Lin Y, Xu J, Su H, Zhong W, Yuan Y, Yu Z, Fang Y, Zhou H, Li C, Huang K.

Clin Transl Oncol. 2015 Jan;17(1):50-6.

PMID:
25015721
2.

p42.3: a promising biomarker for the progression and prognosis of human colorectal cancer.

Yuan XS, Zhang Y, Guan XY, Dong B, Zhao M, Mao LL, Lu YY, Tian XY, Hao CY.

J Cancer Res Clin Oncol. 2013 Jul;139(7):1211-20. doi: 10.1007/s00432-013-1434-0. Epub 2013 Apr 11.

PMID:
23576022
3.

IL-17A in the tumor microenvironment of the human colorectal adenoma-carcinoma sequence.

Cui G, Yuan A, Goll R, Florholmen J.

Scand J Gastroenterol. 2012 Nov;47(11):1304-12. doi: 10.3109/00365521.2012.725089. Epub 2012 Sep 19.

PMID:
22989213
4.

PTK7 overexpression in colorectal tumors: Clinicopathological correlation and prognosis relevance.

Tian X, Yan L, Zhang D, Guan X, Dong B, Zhao M, Hao C.

Oncol Rep. 2016 Oct;36(4):1829-36. doi: 10.3892/or.2016.4983. Epub 2016 Jul 28.

5.

CXCL10 expression and prognostic significance in stage II and III colorectal cancer.

Jiang Z, Xu Y, Cai S.

Mol Biol Rep. 2010 Jul;37(6):3029-36. doi: 10.1007/s11033-009-9873-z. Epub 2009 Oct 10.

PMID:
19821051
6.

Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer.

Larsson A, Fridberg M, Gaber A, Nodin B, Levéen P, Jönsson G, Uhlén M, Birgisson H, Jirström K.

BMC Cancer. 2012 Jul 8;12:282. doi: 10.1186/1471-2407-12-282.

7.

Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer.

Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A.

J Natl Cancer Inst. 2013 Jun 19;105(12):849-59. doi: 10.1093/jnci/djt101. Epub 2013 May 23.

8.

Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer.

Feng B, Xu WB, Zheng MH, Ma JJ, Cai Q, Zhang Y, Ji J, Lu AG, Qu Y, Li JW, Wang ML, Hu WG, Liu BY, Zhu ZG.

J Gastroenterol Hepatol. 2006 Oct;21(10):1596-603.

PMID:
16928223
9.

Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer.

Likui W, Hong W, Shuwen Z.

J Gastrointest Surg. 2010 Jan;14(1):74-81. doi: 10.1007/s11605-009-1035-z. Epub 2009 Sep 18.

PMID:
19763701
10.

Expression of annexin a5 is associated with higher tumor stage and poor prognosis in colorectal adenocarcinomas.

Xue G, Hao LQ, Ding FX, Mei Q, Huang JJ, Fu CG, Yan HL, Sun SH.

J Clin Gastroenterol. 2009 Oct;43(9):831-7. doi: 10.1097/MCG.0b013e31819cc731.

PMID:
19461527
11.

High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer.

Zheng HT, Shi DB, Wang YW, Li XX, Xu Y, Tripathi P, Gu WL, Cai GX, Cai SJ.

Int J Clin Exp Pathol. 2014 May 15;7(6):3174-81. eCollection 2014.

12.

Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer.

Cui G, Qi H, Gundersen MD, Yang H, Christiansen I, Sørbye SW, Goll R, Florholmen J.

Cancer Immunol Immunother. 2015 Feb;64(2):181-90. doi: 10.1007/s00262-014-1624-x. Epub 2014 Oct 17.

PMID:
25324197
13.

Prognostic value of neutrophil distribution in cholangiocarcinoma.

Mao ZY, Zhu GQ, Xiong M, Ren L, Bai L.

World J Gastroenterol. 2015 Apr 28;21(16):4961-8. doi: 10.3748/wjg.v21.i16.4961.

14.

Expression of CIAPIN1 in human colorectal cancer and its correlation with prognosis.

Shi H, Zhou Y, Liu H, Chen C, Li S, Li N, Li X, Zhang X, Zhang H, Wang W, Zhao Q.

BMC Cancer. 2010 Sep 3;10:477. doi: 10.1186/1471-2407-10-477.

15.

High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor.

Droeser RA, Hirt C, Eppenberger-Castori S, Zlobec I, Viehl CT, Frey DM, Nebiker CA, Rosso R, Zuber M, Amicarella F, Iezzi G, Sconocchia G, Heberer M, Lugli A, Tornillo L, Oertli D, Terracciano L, Spagnoli GC.

PLoS One. 2013 May 29;8(5):e64814. doi: 10.1371/journal.pone.0064814. Print 2013.

16.

Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters.

Luo B, Yun X, Fan R, Lin YD, He SJ, Zhang QM, Mo FR, Chen F, Xiao SW, Xie XX.

Int J Clin Exp Pathol. 2013 Nov 15;6(12):2835-45. eCollection 2013.

17.

Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma.

Paik SS, Jang SM, Jang KS, Lee KH, Choi D, Jang SJ.

Ann Surg Oncol. 2009 Feb;16(2):297-303. doi: 10.1245/s10434-008-0221-7. Epub 2008 Dec 3.

PMID:
19050975
18.

Podocalyxin is a marker of poor prognosis in colorectal cancer.

Kaprio T, Fermér C, Hagström J, Mustonen H, Böckelman C, Nilsson O, Haglund C.

BMC Cancer. 2014 Jul 8;14:493. doi: 10.1186/1471-2407-14-493.

19.

An informatics-assisted label-free approach for personalized tissue membrane proteomics: case study on colorectal cancer.

Han CL, Chen JS, Chan EC, Wu CP, Yu KH, Chen KT, Tsou CC, Tsai CF, Chien CW, Kuo YB, Lin PY, Yu JS, Hsueh C, Chen MC, Chan CC, Chang YS, Chen YJ.

Mol Cell Proteomics. 2011 Apr;10(4):M110.003087. doi: 10.1074/mcp.M110.003087. Epub 2011 Jan 5.

20.

MTSS1 overexpression correlates with poor prognosis in colorectal cancer.

Wang D, Xu MR, Wang T, Li T, Zhu Jw.

J Gastrointest Surg. 2011 Jul;15(7):1205-12. doi: 10.1007/s11605-011-1546-2. Epub 2011 May 12.

PMID:
21562916

Supplemental Content

Support Center